US › Healthcare

Aquestive Therapeutics Inc (AQST)

US · Healthcare · Drug Manufacturers - Specialty & Generic

$4.66-3.32%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

$13.8M

Revenue YoY

+38.1%

Net profit

$-22.9M

EPS

$-0.18

EPS estimate

$-0.10

Net margin

-165.5%

EPS came in at -0.18 against a street estimate of -0.10 — a miss of 80.0%.

Key statistics

Market cap

$603.7M

Forward P/E

0.0

P/B

14.15

Book value

$-0.45

EPS (TTM)

$-0.65

52-week high

$7.55

52-week low

$2.93

50-day MA

$4.38

200-day MA

$4.45

Beta

1.47

Analyst view

Analysts rate Aquestive Therapeutics Inc a strong buy (9 buy, 0 hold, 0 sell out of 9) with an average price target of $9.33.

Shareholding

Insiders

2.84%

Institutions

58.63%

Largest institutional holders

Fund	Stake
Bratton Capital Management, L.P.	7.82%
BlackRock Inc	5.98%
RTW INVESTMENTS, LLC	5.92%
Vanguard Capital Management, LLC	3.54%
Federated Hermes Inc	2.48%
Balyasny Asset Management LLC	2.31%
State Street Corp	2.03%
Samsara BioCapital, LLC	1.99%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Aquestive Therapeutics Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.